BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020;12:3053-94. [PMID: 32018226 DOI: 10.18632/aging.102777] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang H, Lu Y, Liu R, Wang L, Liu Q, Han S. A Non-Invasive Nomogram for Preoperative Prediction of Microvascular Invasion Risk in Hepatocellular Carcinoma. Front Oncol 2021;11:745085. [PMID: 35004273 DOI: 10.3389/fonc.2021.745085] [Reference Citation Analysis]
2 Augello G, Emma MR, Azzolina A, Puleio R, Condorelli L, Cusimano A, Giannitrapani L, McCubrey JA, Iovanna JL, Cervello M. The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma. Cancer Lett 2021;519:250-62. [PMID: 34314755 DOI: 10.1016/j.canlet.2021.07.026] [Reference Citation Analysis]
3 Zhuang H, Chen X, Dong F, Zhang Z, Zhou Z, Ma Z, Huang S, Chen B, Zhang C, Hou B. Prognostic values and immune suppression of the S100A family in pancreatic cancer. J Cell Mol Med 2021;25:3006-18. [PMID: 33580614 DOI: 10.1111/jcmm.16343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Marin JJG, Macias RIR, Monte MJ, Romero MR, Asensio M, Sanchez-Martin A, Cives-Losada C, Temprano AG, Espinosa-Escudero R, Reviejo M, Bohorquez LH, Briz O. Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1663. [PMID: 32585893 DOI: 10.3390/cancers12061663] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
5 Zhuang H, Zhou Z, Ma Z, Li Z, Liu C, Huang S, Zhang C, Hou B. Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer. J Cell Mol Med 2020;24:13481-93. [PMID: 33073486 DOI: 10.1111/jcmm.15990] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Augello G, Emma MR, Cusimano A, Azzolina A, Montalto G, McCubrey JA, Cervello M. The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment. Cells 2020;9:E1427. [PMID: 32526891 DOI: 10.3390/cells9061427] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
7 Cao W, Liu X, Zhang Y, Li A, Xie Y, Zhou S, Song L, Xu R, Ma Y, Cai S, Tang X. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy. Biomed Res Int 2021;2021:5556306. [PMID: 33987439 DOI: 10.1155/2021/5556306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ran X, Zhang C, Wang X, Zhao Q, Zhao Q, Yuan C, Kuang Y, Chen X, Chen X. Expression of CD28 in Hepatocellular Carcinoma and Its Prognostic Value. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.118605] [Reference Citation Analysis]
9 McCubrey JA, Yang LV, Abrams SL, Steelman LS, Follo MY, Cocco L, Ratti S, Martelli AM, Augello G, Cervello M. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. Cells 2022;11:2155. [PMID: 35883598 DOI: 10.3390/cells11142155] [Reference Citation Analysis]
10 Wang S, Lv Q, Li X, Omri A. Recent Advances in Drug Delivery Nanocarriers for Targeting Hepatocellular Carcinoma. Journal of Nanomaterials 2022;2022:1-8. [DOI: 10.1155/2022/7798919] [Reference Citation Analysis]
11 Jiang J, Zhang Y, Xu R, Ren L, Chen J, Lu H. PRIM1 promotes the proliferation of hepatocellular carcinoma cells in vitro and in vivo. J Cancer 2020;11:6601-11. [PMID: 33046981 DOI: 10.7150/jca.47870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhou X, Chi Y, Dong Z, Tao T, Zhang X, Pan W, Wang Y. A nomogram combining PPARγ expression profiles and clinical factors predicts survival in patients with hepatocellular carcinoma. Oncol Lett 2021;21:319. [PMID: 33692851 DOI: 10.3892/ol.2021.12581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhuang H, Zhang C, Hou B. GTF2IRD1 overexpression promotes tumor progression and correlates with less CD8+ T cells infiltration in pancreatic cancer. Biosci Rep 2020;40:BSR20202150. [PMID: 32936232 DOI: 10.1042/BSR20202150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Li Z, Zhuang H, Chen X, Zhang Y, Ma Z, Wang S, Yan Q, Zhou Z, Huang S, Zhang C, Hou B, Wang J. Identification of MBOAT2 as an Unfavorable Biomarker Correlated with KRAS Activation and Reduced CD8+ T-Cell Infiltration in Pancreatic Cancer. Journal of Oncology 2022;2022:1-20. [DOI: 10.1155/2022/4269733] [Reference Citation Analysis]
15 Yang J, Xing Z. Ligustilide counteracts carcinogenesis and hepatocellular carcinoma cell-evoked macrophage M2 polarization by regulating yes-associated protein-mediated interleukin-6 secretion. Exp Biol Med (Maywood) 2021;246:1928-37. [PMID: 34053234 DOI: 10.1177/15353702211010420] [Reference Citation Analysis]
16 Niu M, Yi M, Li N, Wu K, Wu K. Advances of Targeted Therapy for Hepatocellular Carcinoma. Front Oncol 2021;11:719896. [PMID: 34381735 DOI: 10.3389/fonc.2021.719896] [Reference Citation Analysis]
17 Mo Z, Ding H, Zhou X, Zeng Z, Long L. Gd-EOB-DTPA-enhanced magnetic resonance imaging may help identify patients with hepatocellular carcinoma eligible for treatment targeted at RAF1. Abdom Radiol (NY) 2022;47:209-20. [PMID: 34738148 DOI: 10.1007/s00261-021-03325-z] [Reference Citation Analysis]
18 Costanzi E, Simioni C, Varano G, Brenna C, Conti I, Neri LM. The Role of Extracellular Vesicles as Shuttles of RNA and Their Clinical Significance as Biomarkers in Hepatocellular Carcinoma. Genes (Basel) 2021;12:902. [PMID: 34207985 DOI: 10.3390/genes12060902] [Reference Citation Analysis]
19 Zhuang H, Zhou Z, Zhang Z, Chen X, Ma Z, Huang S, Gong Y, Zhang C, Hou B. B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8+ T cells in pancreatic cancer. Aging (Albany NY) 2020;13:2310-29. [PMID: 33316775 DOI: 10.18632/aging.202255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Zhuang H, Zhang C, Hou B. FAM83H overexpression predicts worse prognosis and correlates with less CD8+ T cells infiltration and Ras-PI3K-Akt-mTOR signaling pathway in pancreatic cancer. Clin Transl Oncol 2020;22:2244-52. [PMID: 32424701 DOI: 10.1007/s12094-020-02365-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
21 Park HJ, Choi G, Ha S, Kim Y, Choi M, Kim M, Islam MK, Chang Y, Kwon T, Kim D, Jang E, Kim TH, Chang SJ, Kim Y. MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases. Cancers 2022;14:1994. [DOI: 10.3390/cancers14081994] [Reference Citation Analysis]
22 Bezzecchi E, Ronzio M, Mantovani R, Dolfini D. NF-Y Overexpression in Liver Hepatocellular Carcinoma (HCC). Int J Mol Sci 2020;21:E9157. [PMID: 33271832 DOI: 10.3390/ijms21239157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]